glp-1-directed nmda receptor antagonism for obesity treatment Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Agonists | Advances in Therapy Harnessing GLP-1 Receptor Agonists for

Moving beyond food noise to drug noise, GLP-1s are quieting the roar of addiction. Reference: Metabolic medicines and addiction: what GLP-1 receptor agonists might add to substance use care by Fares Qeadan, 4 March 2026, BMJ

Thats how GLP-1s entered the weight loss conversation

Following this, participants were given a 10-minute break, completed subjective questionnaires about their current state and experience, including Visual Analogue Scales (VAS) as described above

With GLP-1 prescriptions averaging around $1,000 per month, these medications now account for over 10% of total employer health plan claims in 2025, according to data cited by the International Foundation of Employee Benefit Plans (IFEBP)

Fair-balance framing, not a purchase recommendation